*Sponsored
Krypton Street Is Initiating Coverage On NanoViricides (NYSE American: NNVC) Starting This Morning—Friday, July 18th, 2025.
Here's What We Can Tell You—So Far…
Public Float Under 16M Shares Suggests There's The Potential For Significant Volatility.
Market Cap Under $28M Places (NNVC) In A Category Where It Could Witness A Higher Potential For Growth Compared To Larger Companies In The Same Space.
Nanoviricide® Platform Designed To Neutralize Vi-rus-es Using A Method That Does Not Rely On Immune System Activation.
Bullish Technical Indicators Across The Short, Medium, And Long Term!
July 18th, 2025 Friday's Watchlist | There Goes The Bell… Consider Watching (NNVC) Closely This Morning Dear Reader, The most transformative innovations in biotech aren't sparked by headlines, but by a foundation of profound scientific research, thoughtful strategy, and the readiness to move quickly when the moment calls for it. NanoViricides (NYSE American: NNVC) may not be a household name yet, but its recent approximate 104% move—from $.94 on April 9th to $1.9195 by May 27th—caught our attention for a reason. With fewer than 16M shares available in the float, a market cap under $28M, and a multitude of bullish technical indicators being reported by Barchart, NanoViricides (NYSE American: NNVC) has found its way back on radar as it nears its 2025 chart highs. Companies of this size, especially in the biotech sector, can witness significant swings if interest begins to shift. And right now, (NNVC) appears to be flying under the radar—an often-overlooked name in a space dominated by larger players. But with this type of setup, smaller entities often have a clearer runway for growth and strategic execution. Now, with real-world urgency unfolding in places like Texas, NanoViricides (NYSE American: NNVC) is supplanting itself atop our watchlist. This company isn't just adapting to a changing health landscape—it's building for it. The Shift: Urgency Meets Innovation
With cases in Texas surpassing 750—including tragic outcomes among school-aged children—the healthcare system is again under intense strain. The CDC has mobilized teams in the region, highlighting the growing severity. This backdrop places renewed focus on entities capable of delivering rapid, scientifically grounded responses. NanoViricides (NYSE: NNVC) is advancing NV-387, a promising broad-spectrum treatment developed using their proprietary nanoviricide® technology. 
Designed to mimic human cell receptors, this unique approach neutralizes vi-rus-es before they can replicate—without relying on immune system support. In a time where emerging strains challenge traditional treatments, this method offers a fresh angle. Inside of NanoViricides (NYSE: NNVC)...
Behind the scenes, NanoViricides (NYSE: NNVC) owns a mortgage-free, cGMP-certified manufacturing facility in Shelton, CT. It's fully equipped to handle both dr-ug substance and product for clinical supply, allowing the company to reduce costs, avoid delays, and accelerate progress. Beyond NV-387, their pipeline includes NV-HHV-101—targeting shingles and other herpes-related conditions. NV-HHV-101 has shown positive tolerability in studies and is advancing toward human trials. The Science That Stands Apart …
NanoViricides (NYSE: NNVC)'s proprietary nanoviricide® platform is more than an innovation—it's a departure from the usual path. Traditional treatments rely on antibodies or other methods that target only parts of a vi-rus, which can be circumvented through mutation. Nanoviricides, on the other hand, replicate the surface of human cells, tricking vi-rus-es into binding as if they were entering a host. Once attached, the nanoviricide engulfs and dismantles the vi-rus—no immune response required. This bind-encapsulate-destroy approach creates a therapeutic pathway that is less vulnerable to vi-rus adaptation. The company's development model is lean and precise. Rather than running costly internal labs, (NNVC) collaborates with academic and government labs for independent testing, ensuring transparent data and efficient capital use. With $10B Market Potential, NanoViricides (NYSE: NNVC) Eyes
Major Breakthrough…
NanoViricides (NYSE: NNVC) is a leader in developing nanomedicine dr-ugs to target vir-uses using its nanoviricide® technology. This technology mimics host cell receptors to trick vir-uses into binding to the nanoviricide, dismantling them and blocking reinfection, providing a more durable solution than traditional antibodies or vax's. Key points:
FDA Progress: Moving toward FDA submission with positive feedback on its NV-HHV-101 dr-ug candidate for herpes vir-uses. Innovative Technology: Nanoviricides can target vir-uses even as they mutate, offering broad protection against Vir-al infections. Manufacturing Facility: The company owns a cGMP-certified facility in Shelton, CT, allowing it to produce dr-ugs in-house, saving time and costs. HerpeCide™ Program: Focused on treating shingles, cold sores, and genital ulcers, with an estimated market size exceeding $10B.
Diverse Pipeline: dr-ugs in development for influenza, HIV, Dengue, and Ebola with promising animal model results. Strong IP Portfolio: Exclusive patents for its TheraCour® technology, securing competitive market space. NanoViricides (NYSE: NNVC) is positioned for growth with its breakthrough technology, broad pipeline, and in-house manufacturing, making it a key player in the fight against Vir-al diseases. 7 Reasons Why NanoViricides (NYSE: NNVC) Is Topping Our Watchlist Friday Morning…
1. Recent Breakout After Alert: Approximate 39% move in under 5 weeks—from a $1.38 open on April 25 to a $1.91+ high on May 27, 2025, kept (NNVC) directly on our watchlist.. 2. Limited Float: With fewer than 16M shares available in the float, there's the potential for significant swings if demand begins to shift. 3. Under The Radar: With a market cap under $28M, (NNVC) could have a higher potential for growth compared to larger companies in the same space. 4. Platform Advantage: Proprietary nanoviricide® technology designed to neutralize vi-rus-es with a post-immunotherapeutic approach. 5. Bullish Technical Indicators: Barchart is reporting a multitude of bullish technical indicators across the short, medium, and long term. 6. NV-387 Progress: Completed Phase 1 with no adverse events; advancing toward Phase 2 for respiratory and emergent vi-rus targets. 7. FDA Pipeline Advancement: NV-HHV-101 Has Gained Early-Stage Validation Through Encouraging Feedback From The FDA. All Eyes On NanoViricides (NYSE: NNVC) Friday Morning…
In a year that has already seen the largest measles outbreak in Texas in over three decades—with over 750 confirmed cases and multiple school-aged deaths—NanoViricides (NYSE: NNVC)'s urgency is matched by the real-world need. Public health agencies have allocated significant emergency resources to respond to this outbreak—highlighting the urgent need for frontline innovation. And while many companies are reactive, NanoViricides (NYSE: NNVC) has built a proactive pipeline. From bird-borne strains to other emerging threats, this is a team working ahead of the curve—with a system designed to adapt to mutation, not be hindered by it. As public attention rises and clinical progress continues, this is one little-known company that could quickly shift from niche to necessary. We have all eyes on (NNVC) this morning. Also—keep a lookout for morning updates. Sincerely, Alex Ramsay
Co-Founder / Managing Editor
Krypton Street Newsletter | 
No comments:
Post a Comment